Immunai Scores $215 Million to Accelerate Mapping of the Immune System

A little more than 18 months after launching, Immunai secured $215 million in a Series B financing round that will help the company advance its bold vision of mapping the body’s immune system in order to enable better detection, diagnosis and treatment of diseases.